On November 12, 2026 Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") reported the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening the Company’s intellectual property protection for a key aspect of Annamycin’s formulation technology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Australian Patent No. 2020303572 was granted to Moleculin and The Board of Regents of The University of Texas System. The patent titled, "Preparation of Preliposomal Annamycin Lyophilizate," addresses the preparation of Annamycin’s formulation.
"Securing this patent in Australia represents another step in our efforts to build a strong international intellectual property position around Annamycin," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "Our formulation technology is an important component of Annamycin’s development, and protecting this technology across international markets supports our broader intellectual property strategy."
Expanding International Protection for Annamycin Formulation Technology
The Australian patent is part of Moleculin’s broader global intellectual property portfolio covering complementary technologies associated with Annamycin, the Company’s investigational anthracycline.
The patent portfolio includes granted or allowed patents in the United States, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore and Taiwan. The application has also been accepted in South Africa, where formal grant is pending, while applications remain pending in additional jurisdictions, including South Korea.
Moleculin’s global patent strategy also encompasses additional technology areas, including methods for reconstituting liposomal Annamycin and lung-targeted anticancer therapies using liposomal Annamycin. Together, these efforts reflect the Company’s focus on establishing intellectual property protection across multiple aspects of Annamycin’s development and in key international markets.
Annamycin is an investigational anthracycline designed to address limitations associated with conventional anthracyclines. The drug candidate is being evaluated in clinical development for acute myeloid leukemia (AML) and other difficult-to-treat cancers.
(Press release, Moleculin, NOV 12, 2026, View Source [SID1234674679])